Tucatinib,Trastuzumab,fulvestrant
Seagen
['t-dxd', 'tucatinib']
important data that i have been waiting for. 100 pts. activity of the tucatinib triplet after progression on t-dxd. median pfs 4.7 months, median os 13 months. #asco23 #asco2023 #asco 
A dedicated conference for oncology held under the theme "Access. Educate. Collaborate"